The FDA approved Oct. 8 the first treatment for a rare skin disease that causes pain when exposed to sunlight.
Australian drugmaker Clinuvel received orphan status for its treatment, Scenesse, which is an implant that is inserted under the skin.
The treatment is designed for adults with erythropoietic protoporphyria. For patients with the rare disorder, light exposure can be extremely painful and cause skin redness and thickening.
Side effects of the implant include implant site reactions, nausea, pain and fatigue.
Read the full news release here.